Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

(2014) H. E. Kohrt et al.   BLOOD

Ibrutinib in B-cell Lymphomas

(2014) Kami Maddocks et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model

(2014) Steve Oghumu et al.   IMMUNOLOGY

Characterization of Cross-Protection by Genetically Modified Live-AttenuatedLeishmania donovaniParasites againstLeishmania mexicana

(2014) Ranadhir Dey et al.   JOURNAL OF IMMUNOLOGY

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

DC-based immunotherapy for hematological malignancies

(2013) Toshio Kitawaki   INTERNATIONAL JOURNAL OF HEMATOLOGY

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

(2013) Jan A. Burger et al.   LEUKEMIA & LYMPHOMA

Dendritic cells and other innate determinants of T helper cell polarisation

(2013) Kevin P. Walsh et al.   TRENDS IN IMMUNOLOGY

Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia

(2012) Farhad Jadidi-Niaragh et al.   TUMOR BIOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-γ production by natural killer cells

(2011) Joan Ní Gabhann et al.   CLINICAL IMMUNOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Th17 Cells Are Involved in the Local Control of Tumor Progression in Primary Intraocular Lymphoma

(2011) Claire Galand et al.   PLoS One

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

The Unexpected Role for the Aryl Hydrocarbon Receptor on Susceptibility to Experimental Toxoplasmosis

(2010) Yuriko Sanchez et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Cutting Edge: CTLA-4-B7 Interaction Suppresses Th17 Cell Differentiation

(2010) H. Ying et al.   JOURNAL OF IMMUNOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

(2009) I. Kryczek et al.   BLOOD

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

(2009) Natalia Martin-Orozco et al.   IMMUNITY

Protumor vs Antitumor Functions of IL-17

(2009) G. Murugaiyan et al.   JOURNAL OF IMMUNOLOGY

CD28 Co-Stimulation Down Regulates Th17 Development

(2009) Salim Bouguermouh et al.   PLoS One

Tumor-specific Th17-polarized cells eradicate large established melanoma

(2008) P. Muranski et al.   BLOOD